Tenax Therapeutics Phase 3 trial of TNX-103 misses primary endpoint
Tweet Send to a Friend
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced topline results from its Phase 3 LEVEL clinical trial evaluating TNX-103, an oral form ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
